Analyst Reco. Revolution Medicines, Inc.

Equities

RVMD

US76155X1000

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
40.34 ^USD	+0.47%		+5.24%	+40.66%

Jun. 05	Revolution Medicines Insider Sold Shares Worth $299,942, According to a Recent SEC Filing	MT
May. 09	Wedbush Raises Price Target on Revolution Medicines to $46 From $42, Maintains Outperform Rating	MT

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Wedbush Raises Price Target on Revolution Medicines to $46 From $42, Maintains Outperform Rating	May. 09	MT
Oppenheimer Adjusts Revolution Medicines Price Target to $45 From $43, Maintains Outperform Rating	Apr. 12	MT
Needham Adjusts Revolution Medicines' Price Target to $46 From $36, Keeps Buy Rating	Apr. 12	MT
Piper Sandler Starts Revolution Medicines With Overweight Rating, $43 Price Target	Mar. 11	MT
HC Wainwright Raises Revolution Medicines Price Target to $44 From $28, Maintains Buy Rating	Mar. 08	MT
Wedbush Adjusts Revolution Medicines' Price Target to $42 From $41, Keeps Outperform Rating	Feb. 27	MT
Wedbush Starts Revolution Medicines With Outperform Rating, $41 Price Target	Jan. 04	MT
UBS Initiates Coverage on Revolution Medicines With Buy Rating, $40 Price Target	Dec. 20	MT
Raymond James Starts Revolution Medicines With Outperform Rating, Price Target is $30	Nov. 16	MT
Oppenheimer Raises Revolution Medicines Price Target to $43 From $40, Maintains Outperform Rating	23-10-23	MT
Needham Adjusts Revolution Medicines Price Target to $36 From $34, Maintains Buy Rating	23-10-23	MT
Stifel Raises Revolution Medicines' Price Target to $47 From $37, Keeps Buy Rating	23-09-21	MT
Needham Adjusts Price Target on Revolution Medicines to $34 From $35, Maintains Buy Rating	23-08-09	MT
Oppenheimer Adjusts Revolution Medicines Price Target to $40 From $35, Maintains Outperform Rating	23-08-02	MT
Needham Adjusts Price Target on Revolution Medicines to $35 From $31, Maintains Buy Rating	23-08-02	MT
Needham Adjusts Price Target on Revolution Medicines to $32 From $34, Maintains Buy Rating	23-05-09	MT
Goldman Sachs Adjusts Price Target on Revolution Medicines to $23 From $20, Maintains Neutral Rating	23-03-01	MT
Oppenheimer Adjusts Revolution Medicines Price Target to $35 From $30, Maintains Outperform Rating	23-02-28	MT
Needham Adjusts Revolution Medicines' Price Target to $38 From $32, Maintains Buy Rating	23-02-28	MT
JPMorgan Upgrades Revolution Medicines to Overweight From Neutral, Boosts Price Target to $38 From $32	23-02-28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Revolution Medicines, Inc.

Equities

RVMD

US76155X1000

Analyst Reco.

Filters